Biomarin Pharmaceutical Inc (BMRN)

Return on equity (ROE)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	205,455	167,645	147,021	99,991	71,615	141,561	83,912	54,070	39,347	-64,080	10,846	832,143	790,019	854,029	852,025	122,258	114,006	-23,848	-42,522	-110,178
Total stockholders’ equity	US$ in thousands	5,073,820	4,951,550	4,896,900	4,782,830	4,659,040	4,603,160	4,568,510	4,499,740	4,386,240	4,265,670	4,261,080	4,236,500	4,162,010	4,100,930	4,053,890	3,236,680	3,239,960	3,122,380	3,074,400	2,960,950
ROE		4.05%	3.39%	3.00%	2.09%	1.54%	3.08%	1.84%	1.20%	0.90%	-1.50%	0.25%	19.64%	18.98%	20.83%	21.02%	3.78%	3.52%	-0.76%	-1.38%	-3.72%

March 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $205,455K ÷ $5,073,820K
= 4.05%

Biomarin Pharmaceutical Inc's return on equity (ROE) has shown fluctuations over the past few quarters. As of March 31, 2024, the ROE stands at 4.05%, which is an improvement compared to the previous quarter's ROE of 3.39%. The company's ROE has been on a positive trajectory since September 2021 when it was -1.50%.

ROE is a measure of a company's profitability that indicates how efficiently it is using its equity to generate earnings. Biomarin Pharmaceutical Inc's ROE has been relatively low in recent quarters, indicating challenges in efficiently utilizing shareholders' equity.

The significant increase in ROE in the quarters ended March 31, 2021, and December 31, 2020, to around 20% suggests that the company experienced a period of high profitability during that time. However, the decreasing trend in ROE in subsequent quarters may point towards challenges or changes in the company's operations or financial performance.

It is important for investors and stakeholders to continue monitoring Biomarin Pharmaceutical Inc's ROE to assess the company's profitability and how well it is utilizing shareholder equity to generate returns. Further analysis and exploration into the factors influencing the ROE trends may provide insights into the company's financial health and performance.